US FDA says no overall risk of atrial fibrillation with bisphosphonates
This article was originally published in Scrip
Executive Summary
A review of clinical trial data from four pharmaceutical firms shows no overall risk of atrial fibrillation in patients taking certain bisphosphonates for osteoporosis, the US FDAsaid in an update on its website. It added, that, based on the data available, there is no reason for healthcare professionals to alter their prescribing patterns for bisphosphonates.